Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More Insulin Innovation To Come, Says Novo CEO Sorensen

This article was originally published in The Pink Sheet Daily

Executive Summary

Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices

You may also be interested in...

Degludec Advisory Committee Is Another De Facto Delay For Novo

FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.

New Long-Acting Insulin Offerings Could Derail Lantus Franchise

Companies presented data at ADA that could give patients options other than Lantus, but Sanofi is fighting back with a strategy to retain them.

Novo Nordisk Brings Renewed Education Efforts, But Not New Products, To Japan In 2012

Novo Nordisk pushes the benefits of early diabetes treatment to spur Victoza and insulin growth.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts